All obesity articles
-
NewsNovo secures €1.17bn long-acting injectable deal with Nanexa
Licensing agreement focuses on a delivery technology that provides sustained-release injectable peptides and offers potential to reduce treatment burden in obesity and type 2 diabetes.
-
NewsNovo Nordisk tightens obesity market focus with ‘Novo’ name change
The Danish pharmaceutical giant hopes the strategic rebranding and modernising its culture will sharpen the company’s competitive edge in the rapidly evolving obesity and diabetes therapeutics landscape.
-
NewsGenentech licenses Hanmi’s UCN2 obesity candidate in $2.3bn deal
Potential first-in-class treatment HM17321 offers a non-incretin mechanism of action and differentiated profile from existing GLP-1-based treatments for obesity.
-
-
NewsOptimised semaglutide formulation could advance peptide-based oral delivery
Study provides insight on enhancing the formulation development of GLP-1-targeting therapies for obesity and diabetes.
-
NewsBoehringer’s GLP-1 dual agonist survodutide shines in phase III trial
Survodutide could become first global glucagon/GLP-1 dual agonist, new phase III findings suggest.
-
NewsFDA approves Lilly’s small molecule obesity pill Foundayo
New GLP-1 therapy Foundayo is Eli Lilly’s second obesity medicine to be authorised for use in the US.
-
NewsEli Lilly doubles down on supply chain investment in Asia
Pharma giant to strengthen manufacturing capabilities in Japan and add capacity in China for its first oral GLP-1 therapy candidate, orforglipron.
-
NewsNovo Nordisk expands oral GLP-1 manufacturing capacity in Ireland
Near €500 million investment will increase the firm’s capacity to produce tablet versions of its obesity and diabetes medicines.
-
NewsNovo Nordisk strikes $2.1bn oral obesity biologic deal with Vivtex
Drug delivery partnership to advance next-generation oral therapies and help Novo Nordisk expand its obesity and diabetes portfolio.
-
NewsRoche GLP-1 produces “robust” weight loss in late-stage obesity trial
The pharma company’s injectable GLP-1/GIP receptor agonist CT-388 is an important element of its weight loss strategy and also delivered benefits for pre-diabetic patients.
-
News
US oral GLP-1 first as Novo Nordisk launches Wegovy pill
The obesity drug’s new formulation gains an important opportunity to define the market before regulators finish assessing Lilly’s rival orforglipron.
-
NewsPfizer boosts its obesity plans with $2bn GLP-1 YaoPharma deal
The move builds on its recent billion-dollar acquisition of the obesity-focused biopharma company Metsera.
-
News
Pfizer’s Metsera hunger sees it beat Novo Nordisk’s obesity biopharma offer
The deal puts Pfizer’s plans to acquire the US firm, and a portfolio that includes injectable GLP-1 drugs, back on track.
-
NewsAstraZeneca seals obesity deal as Pfizer-Novo Nordisk battle for Metsera
After Wegovy and Zepbound's success, competition for the next potential weight loss blockbuster heats up.
-
News
Pfizer and Novo Nordisk battle for obesity market dominance
Novo Nordisk’s “bold” $6.5 billion bid subject to a final verdict by Metsera’s board of directors.
-
NewsLilly outlines $1bn India manufacturing expansion
The investment will cover CMO collaborations and a new manufacturing and quality hub in Hyderabad.
-
NewsLilly to site next US manufacturing facility in Texas
The new $6.5 billion Houston site will manufacture active pharmaceutical ingredients (APIs) in support of the company’s pipeline of small molecule medicines.
-
NewsPfizer acquires Metsera and its GLP-1 candidates in new $4.9bn obesity play
The deal with the US biopharma adds a portfolio of clinical-stage incretin and amylin research programmes to its pipeline.
-
News
Obesity drug competition fuels Novo Nordisk restructure
The company’s CEO says the shift will help prioritise investment into obesity and diabetes, the company’s leading therapy areas.